Meeting
2021 ASCO Annual Meeting
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
Authors
Jian Li
Beijing Cancer Hospital, Beijing, China
Jian Li , Ye Xu , Aimin Zang , Yunong Gao , Quanli Gao , Yanqiao Zhang , Dong Wang , Jianming Xu , Ying Yuan , Haiping Jiang , Jieer Ying , Chunmei Shi , Yanhong Deng , Jing Wang , Tianshu Liu , Yi Huang , Zhezhen Li , Huanli Wang , Shou Liu , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Clinical Trial Registration Number
NCT03736889
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2569)
DOI
10.1200/JCO.2021.39.15_suppl.2569
Abstract #
2569
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
First Author: Jian Li
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).
First Author: Shun Zhang